A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513884-20-00

Acronym

ID-069A302

Enrollment

Registered

2024-11-05

Start date

2019-03-13

Completion date

Unknown

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry disease

Brief summary

Treatment-emergent AEs and SAEs

Interventions

DRUGLucerastat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Treatment-emergent AEs and SAEs	—

Countries

Austria, Belgium, France, Germany, Norway, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026

A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.